XCSEVIRO
Market cap12mUSD
Dec 23, Last price
11.90DKK
1D
-1.65%
1Q
105.17%
IPO
-86.63%
Name
ViroGates A/S
Chart & Performance
P/E
—
P/S
13.17
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
3.16%
Rev. gr., 5y
16.07%
Revenues
7m
-54.02%
Net income
-12m
L+25.40%
CFO
-12m
L-14.69%
Profile
ViroGates A/S develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a blood test that measures the soluble urokinase plasminogen activator receptor (suPAR) protein in the bloodstream used for emergency departments in hospitals to improve clinical decisions on hospitalization or discharge of acute medical patients and reduce healthcare cost. The company also provides suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the suPAR level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging; and suPARnostic ELISA that provides fully quantitative results. Its suPAR prognostic tool used in various diseases, such as cardiovascular, kidney, cancer, diabetes, liver, infectious, respiratory, and rheumatic. The company was incorporated in 2000 and is headquartered in Birkerød, Denmark.
Valuation
Title DKK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 6,987 -54.02% | 15,197 98.50% | 7,656 43.00% | ||||||
Cost of revenue | 19,551 | 26,042 | 26,445 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (12,564) | (10,845) | (18,789) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (994) | (1,230) | (1,302) | ||||||
Tax Rate | |||||||||
NOPAT | (11,570) | (9,615) | (17,487) | ||||||
Net income | (12,096) 25.40% | (9,646) -45.39% | (17,663) -5.73% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 13,015 | 9,308 | 2,776 | ||||||
BB yield | -62.47% | -5.50% | -0.47% | ||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | 5,300 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 574 | ||||||||
Net debt | (10,727) | (10,067) | (15,034) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (12,179) | (14,276) | (21,437) | ||||||
CAPEX | |||||||||
Cash from investing activities | 12 | (13) | (4) | ||||||
Cash from financing activities | 18,315 | 9,308 | 2,776 | ||||||
FCF | (9,787) | (16,111) | (18,446) | ||||||
| Balance | |||||||||
Cash | 16,027 | 9,878 | 14,859 | ||||||
Long term investments | 189 | 175 | |||||||
Excess cash | 15,678 | 9,307 | 14,651 | ||||||
Stockholders' equity | 17,008 | 16,088 | 16,426 | ||||||
Invested Capital | 6,629 | 6,781 | 1,775 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 3,461 | 4,221 | 4,089 | ||||||
Price | 6.02 -84.99% | 40.10 -72.15% | 144.00 76.69% | ||||||
Market cap | 20,835 -87.69% | 169,275 -71.25% | 588,823 80.76% | ||||||
EV | 10,108 | 159,208 | 573,789 | ||||||
EBITDA | (12,524) | (10,670) | (18,572) | ||||||
EV/EBITDA | |||||||||
Interest | 569 | 112 | 194 | ||||||
Interest/NOPBT | |||||||||